<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.molecularpain.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Molecular Pain - Latest Articles</title>
        <link>http://www.molecularpain.com</link>
        <description>The latest research articles published by Molecular Pain</description>
        <dc:date>2010-03-05T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.molecularpain.com/content/6/1/15" />
                                <rdf:li rdf:resource="http://www.molecularpain.com/content/6/1/14" />
                                <rdf:li rdf:resource="http://www.molecularpain.com/content/6/1/13" />
                                <rdf:li rdf:resource="http://www.molecularpain.com/content/6/1/12" />
                                <rdf:li rdf:resource="http://www.molecularpain.com/content/6/1/11" />
                                <rdf:li rdf:resource="http://www.molecularpain.com/content/6/1/10" />
                                <rdf:li rdf:resource="http://www.molecularpain.com/content/6/1/9" />
                                <rdf:li rdf:resource="http://www.molecularpain.com/content/6/1/8" />
                                <rdf:li rdf:resource="http://www.molecularpain.com/content/6/1/7" />
                                <rdf:li rdf:resource="http://www.molecularpain.com/content/6/1/6" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.molecularpain.com/content/6/1/15">
        <title>Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice</title>
        <description>Background:
Cisplatin is primarily used for treatment of ovarian and testicular cancer. Oxaliplatin is the only effective treatment for metastatic colorectal cancer. Both are known to cause dose related, cumulative toxic effects on the peripheral nervous system and thirty to forty percent of cancer patients receiving these agents experience painful peripheral neuropathy. The mechanisms underlying painful platinum-induced neuropathy remain poorly understood. Previous studies have demonstrated important roles for TRPV1, TRPM8, and TRPA1 in inflammation and injury induced pain.
Results:
In this study, using real-time, reverse transcriptase, polymerase chain reaction (RT-PCR), we analyzed the expression of TRPV1, TRPM8, and TRPA1 induced by cisplatin or oxaliplatin in vitro and in vivo. For in vitro studies, cultured E15 rat dorsal root ganglion (DRG) neurons were treated for up to 48 hours with cisplatin or oxaliplatin. For in vivo studies, trigeminal ganglia (TG) were isolated from mice treated with platinum drugs for three weeks. We show that cisplatin and oxaliplatin-treated DRG neurons had significantly increased in TRPV1, TRPA1, and TRPM8 mRNA expression. TG neurons from cisplatin treated mice had significant increases in TRPV1 and TRPA1 mRNA expression while oxaliplatin strongly induced only TRPA1. Furthermore, compared to the cisplatin-treated wild-type mice, cisplatin-treated TRPV1-null mice developed mechanical allodynia but did not exhibit enhancement of noxious heat- evoked pain responses. Immunohistochemistry studies showed that cisplatin-treated mice had no change in the proportion of the TRPV1 immunopositive TG neurons.
Conclusion:
These results indicate that TRPV1 and TRPA1 could contribute to the development of thermal hyperalgesia and mechanical allodynia following cisplatin-induced painful neuropathy but that TRPV1 has a crucial role in cisplatin-induced thermal hyperalgesia in vivo.</description>
        <link>http://www.molecularpain.com/content/6/1/15</link>
                <dc:creator>Lauren Ta</dc:creator>
                <dc:creator>Allan Bieber</dc:creator>
                <dc:creator>Susan Carlton</dc:creator>
                <dc:creator>Charles Loprinzi</dc:creator>
                <dc:creator>Philip Low</dc:creator>
                <dc:creator>Anthony Windebank</dc:creator>
                <dc:source>Molecular Pain 2010, 6:15</dc:source>
        <dc:date>2010-03-05T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-8069-6-15</dc:identifier>
        <prism:publicationName>Molecular Pain</prism:publicationName>
        <prism:issn>1744-8069</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>15</prism:startingPage>
        <prism:publicationDate>2010-03-05T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularpain.com/content/6/1/14">
        <title>TRPA1 modulation of spontaneous and mechanically evoked firing of spinal neurons in uninjured, osteoarthritic, and inflamed rats</title>
        <description>Background:
There is growing evidence supporting a role for TRPA1 receptors in the neurotransmission of peripheral mechanical stimulation.  In order to enhance understanding of TRPA1 contributions to mechanotransmission, we examined the effects of a selective TRPA1 receptor antagonist, A-967079, on spinal neuronal activity following peripheral mechanical stimulation in uninjured, CFA-inflamed, and osteoarthritc (OA) rats. Results. Systemic injection of A-967079 (30 umol/kg, i.v.) decreased the responses of wide dynamic range (WDR), and nociceptive specific (NS) neurons following noxious pinch stimulation of the ipsilateral hind paw in uninjured and CFA-inflamed rats. Similarly, A-967079 reduced the responses of WDR neurons to high-intensity mechanical stimulation (300 g von Frey hair) of the knee joint in both OA and OA-sham rats. WDR neuronal responses to low-intensity mechanical stimulation (10 g von Frey hair) were also reduced by A-967079 administration to CFA-inflamed rats, but no effect was observed in uninjured rats. Additionally, the spontaneous activity of WDR neurons was decreased after A-967079 injection in CFA-inflamed rats but was unaltered in uninjured, OA, and OA-sham animals.
Conclusions:
Blockade of TRPA1 receptors disrupts transmission of high-intensity mechanical stimulation to the spinal cord in both uninjured and injured rats indicating that TRPA1 receptors have an important role in noxious mechanosensation in both normal and pathological conditions. TRPA1 receptors also contribute to the transmission of low-intensity mechanical stimulation, and to the modulation of spontaneous WDR firing, but only after an inflammatory injury.</description>
        <link>http://www.molecularpain.com/content/6/1/14</link>
                <dc:creator>Steve McGaraughty</dc:creator>
                <dc:creator>Katharine Chu</dc:creator>
                <dc:creator>Richard Perner</dc:creator>
                <dc:creator>Stanley Didomenico</dc:creator>
                <dc:creator>Michael Kort</dc:creator>
                <dc:creator>Philip Kym</dc:creator>
                <dc:source>Molecular Pain 2010, 6:14</dc:source>
        <dc:date>2010-03-05T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-8069-6-14</dc:identifier>
        <prism:publicationName>Molecular Pain</prism:publicationName>
        <prism:issn>1744-8069</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>14</prism:startingPage>
        <prism:publicationDate>2010-03-05T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularpain.com/content/6/1/13">
        <title>Nitric oxide synthase modulates CFA-induced thermal hyperalgesia through cytokine regulation in mice</title>
        <description>Background:
Although it has been largely demonstrated that nitric oxide synthase (NOS), a key enzyme for nitric oxide (NO) production, modulates inflammatory pain, the molecular mechanisms underlying these effects remain to be clarified. Here we asked whether cytokines, which have well-described roles in inflammatory pain, are downstream targets of NO in inflammatory pain and which of the isoforms of NOS are involved in this process.
Results:
Intraperitoneal (i.p.) pretreatment with 7-nitroindazole sodium salt (7-NINA, a selective neuronal NOS inhibitor), aminoguanidine hydrochloride (AG, a selective inducible NOS inhibitor), L-N(G)-nitroarginine methyl ester (L-NAME, a non-selective NOS inhibitor), but not L-N(5)-(1-iminoethyl)-ornithine (L-NIO, a selective endothelial NOS inhibitor), significantly attenuated thermal hyperalgesia induced by intraplantar (i.pl.) injection of complete Freund&apos;s adjuvant (CFA). Real-time reverse transcription-polymerase chain reaction (RT-PCR) revealed a significant increase of nNOS, iNOS, and eNOS gene expression, as well as tumor necrosis factor-alpha (TNF), interleukin-1 beta (IL-1 belta), and interleukin-10 (IL-10) gene expression in plantar skin, following CFA. Pretreatment with the NOS inhibitors prevented the CFA-induced increase of the pro-inflammatory cytokines TNF and IL-1 belta. The increase of the anti-inflammatory cytokine IL-10 was augmented in mice pretreated with 7-NINA or L-NAME, but reduced in mice receiving AG or L-NIO. NNOS-, iNOS- or eNOS-knockout (KO) mice had lower gene expression of TNF, IL-1 belta, and IL-10 following CFA, overall corroborating the inhibitor data.
Conclusion:
These findings lead us to propose that inhibition of NOS modulates inflammatory thermal hyperalgesia by regulating cytokine expression.</description>
        <link>http://www.molecularpain.com/content/6/1/13</link>
                <dc:creator>Yong Chen</dc:creator>
                <dc:creator>Michael Boettger</dc:creator>
                <dc:creator>Andreas Reif</dc:creator>
                <dc:creator>Angelika Schmitt</dc:creator>
                <dc:creator>Nurcan Uceyler</dc:creator>
                <dc:creator>Claudia Sommer</dc:creator>
                <dc:source>Molecular Pain 2010, 6:13</dc:source>
        <dc:date>2010-03-02T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-8069-6-13</dc:identifier>
        <prism:publicationName>Molecular Pain</prism:publicationName>
        <prism:issn>1744-8069</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>13</prism:startingPage>
        <prism:publicationDate>2010-03-02T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularpain.com/content/6/1/12">
        <title>Kinin B1 receptors contributes to acute pain following minor surgery in humans </title>
        <description>Background:
Kinins play an important role in regulation of pain and hyperalgesia after tissue injury and inflammation by activating two types of G-protein-coupled receptors, the kinin B1 and B2 receptors. It is generally accepted that the B2 receptor is constitutively expressed, whereas the B1 receptor is induced in response to inflammation. However, little is known about the regulatory effects of kinin receptors on the onset of acute inflammation and inflammatory pain in humans. The present study investigated the changes in gene expression of kinin receptors and the levels of their endogenous ligands at an early time point following tissue injury and their relation to clinical pain, as well as the effect of COX-inhibition on their expression levels.
Results:
Tissue injury resulted in a significant up-regulation in the gene expression of B1 and B2 receptors at 3 hours post-surgery, the onset of acute inflammatory pain. Interestingly, the up-regulation in the gene expression of B1 and B2 receptors was positively correlated to pain intensity only after ketorolac treatment, signifying an interaction between prostaglandins and kinins in the inflammatory pain process. Further, the gene expression of both B1 and B2 receptors were correlated. Following tissue injury, B1 ligands des-Arg9-BK and des-Arg10-KD were significantly lower at the third hour compared to the first 2 hours in both the placebo and the ketorolac treatment groups but did not differ significantly between groups. Tissue injury also resulted in the down-regulation of TRPV1 gene expression at 3 hours post-surgery with no significant effect by ketorolac treatment. Interestingly, the change in gene expression of TRPV1 was correlated to the change in gene expression of B1 receptor but not B2 receptor.
Conclusions:
These results provide evidence at the transcriptional level in a clinical model of tissue injury that up-regulation of kinin receptors are involved in the development of the early phase of inflammation and inflammatory pain. The up-regulation of B1 receptors may contribute to acute inflammatory pain through TRPV1 activation.</description>
        <link>http://www.molecularpain.com/content/6/1/12</link>
                <dc:creator>May Hamza</dc:creator>
                <dc:creator>Xiao-Min Wang</dc:creator>
                <dc:creator>Albert Adam</dc:creator>
                <dc:creator>Jaime Brahim</dc:creator>
                <dc:creator>Janet Rowan</dc:creator>
                <dc:creator>Gilberto Carmona</dc:creator>
                <dc:creator>Raymond Dionne</dc:creator>
                <dc:source>Molecular Pain 2010, 6:12</dc:source>
        <dc:date>2010-02-13T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-8069-6-12</dc:identifier>
        <prism:publicationName>Molecular Pain</prism:publicationName>
        <prism:issn>1744-8069</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>12</prism:startingPage>
        <prism:publicationDate>2010-02-13T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularpain.com/content/6/1/11">
        <title>Expression genetics identifies spinal mechanisms supporting formalin late phase behaviors</title>
        <description>Background:
Formalin injection into rodent hind paws is one of the most commonly employed pain assays. The resulting nocifensive behaviors can be divided into two phases differing in timing, duration and underlying mechanisms. Spinal sensitization has long been felt to participate in the second phase of this response, although this sensitization is incompletely understood. By using correlative analysis between spinal gene expression and mouse strain-dependent intensity of late phase behavior, we hypothesized genes participating in variability of the response could be identified.
Results:
Late phase formalin behavior scores among 10 inbred mouse strains were correlated with a spinal cord gene expression database constructed using expression arrays. Messenger RNA levels for several genes were highly correlated with the late phase behavioral responses. Most of these genes had already been implicated in mechanisms regulating pain and analgesia. One of the most strongly correlated genes, Mapk8 coding for c-Jun N-terminal kinase 1 (JNK1), was chosen for further analysis. Studies using additional strains of mice confirmed that spinal cord mRNA expression levels of Mapk8 followed the pattern predicted by strain-specific levels of formalin behavior. Interestingly, spinal cord JNK1 protein levels displayed an inverse relationship with mRNA measurements. Finally, intrathecal injections of the selective JNK inhibitor, SP600125, selectively reduced late phase licking behavior.
Conclusions:
Wide differences in pain behaviors, including those resulting from the injection of formalin, can be observed in inbred strains of mice suggesting strong genetic influences. Correlating levels of gene expression in tissues established to be mechanistically implicated in the expression of specific behaviors can identify genes involved in the behaviors of interest. Comparing formalin late phase behavior levels with spinal cord gene expression yielded several plausible gene candidates, including the Mapk8 gene. Additional molecular and pharmacologic evidence confirmed a functional role for this gene in supporting formalin late phase responses.</description>
        <link>http://www.molecularpain.com/content/6/1/11</link>
                <dc:creator>Xiangqi Li</dc:creator>
                <dc:creator>Peyman Sahbaie</dc:creator>
                <dc:creator>Ming Zheng</dc:creator>
                <dc:creator>Jennifer Ritchie</dc:creator>
                <dc:creator>Gary Peltz</dc:creator>
                <dc:creator>Jeffrey Mogil</dc:creator>
                <dc:creator>J. David Clark</dc:creator>
                <dc:source>Molecular Pain 2010, 6:11</dc:source>
        <dc:date>2010-02-11T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-8069-6-11</dc:identifier>
        <prism:publicationName>Molecular Pain</prism:publicationName>
        <prism:issn>1744-8069</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>11</prism:startingPage>
        <prism:publicationDate>2010-02-11T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularpain.com/content/6/1/10">
        <title>Facilitation of synaptic transmission and pain responses 
by CGRP in the amygdala of normal rats</title>
        <description>Calcitonin gene-related peptide (CGRP) plays an important role in peripheral and central sensitization. CGRP also is a key molecule in the spino-parabrachial-amygdaloid pain pathway. Blockade of CGRP1 receptors in the spinal cord or in the amygdala has antinociceptive effects in different pain models. Here we studied the electrophysiological mechanisms of behavioral effects of CGRP in the amygdala in normal animals without tissue injury.Whole-cell patch-clamp recordings of neurons in the latero-capsular division of the central nucleus of the amygdala (CeLC) in rat brain slices showed that CGRP (100 nM) increased excitatory postsynaptic currents (EPSCs) at the parabrachio-amygdaloid (PB-CeLC) synapse, the exclusive source of CGRP in the amygdala. Consistent with a postsynaptic mechanism of action, CGRP increased amplitude, but not frequency, of miniature EPSCs and did not affect paired-pulse facilitation. CGRP also increased neuronal excitability. CGRP-induced synaptic facilitation was reversed by an NMDA receptor antagonist (AP5, 50 &#956;M) or a PKA inhibitor (KT5720, 1 &#956;M), but not by a PKC inhibitor (GF109203X, 1 &#956;M). Stereotaxic administration of CGRP (10 &#956;M, concentration in microdialysis probe) into the CeLC by microdialysis in awake rats increased audible and ultrasonic vocalizations and decreased hindlimb withdrawal thresholds. Behavioral effects of CGRP were largely blocked by KT5720 (100 &#956;M) but not by GF109203X (100 &#956;M).The results show that CGRP in the amygdala exacerbates nocifensive and affective behavioral responses in normal animals through PKA- and NMDA receptor-dependent postsynaptic facilitation. Thus, increased CGRP levels in the amygdala might trigger pain in the absence of tissue injury.</description>
        <link>http://www.molecularpain.com/content/6/1/10</link>
                <dc:creator>Jeong Han</dc:creator>
                <dc:creator>Hita Adwanikar</dc:creator>
                <dc:creator>Zhen Li</dc:creator>
                <dc:creator>Guangchen Ji</dc:creator>
                <dc:creator>Volker Neugebauer</dc:creator>
                <dc:source>Molecular Pain 2010, 6:10</dc:source>
        <dc:date>2010-02-08T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-8069-6-10</dc:identifier>
        <prism:publicationName>Molecular Pain</prism:publicationName>
        <prism:issn>1744-8069</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>10</prism:startingPage>
        <prism:publicationDate>2010-02-08T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularpain.com/content/6/1/9">
        <title>Alteration of primary afferent activity following inferior alveolar nerve transection in rats</title>
        <description>Background:
In order to evaluate the neural mechanisms underlying the abnormal facial pain that may develop following regeneration of the injured inferior alveolar nerve (IAN), the properties of the IAN innervated in the mental region were analyzed.
Results:
Fluorogold (FG) injection into the mental region 14 days after IAN transection showed massive labeling of trigeminal ganglion (TG). The escape threshold to mechanical stimulation of the mental skin was significantly lower (i.e. mechanical allodynia) at 11-14 days after IAN transection than before surgery. The background activity, mechanically evoked responses and afterdischarges of IAN A&#948;-fibers were significantly higher in IAN-transected rats than naive. The small/medium diameter TG neurons showed an increase in both tetrodotoxin (TTX)-resistant (TTX-R) and -sensitive (TTX-S) sodium currents (I
Na) and decrease in total potassium current, transient current (I
A) and sustained current (I
K) in IAN-transected rats. The amplitude, overshoot amplitude and number of action potentials evoked by the depolarizing pulses after 1 &#956;M TTX administration in TG neurons were significantly higher, whereas the threshold current to elicit spikes was smaller in IAN-transected rats than naive. Resting membrane potential was significantly smaller in IAN-transected rats than that of naive.
Conclusions:
These data suggest that the increase in both TTX-S I
Na and TTX-R I
Na and the decrease in I
A and I
k in small/medium TG neurons in IAN-transected rats are involved in the activation of spike generation, resulting in hyperexcitability of A&#948;-IAN fibers innervating the mental region after IAN transection.</description>
        <link>http://www.molecularpain.com/content/6/1/9</link>
                <dc:creator>Kazuharu Nakagawa</dc:creator>
                <dc:creator>Mamoru Takeda</dc:creator>
                <dc:creator>Yoshiyuki Tsuboi</dc:creator>
                <dc:creator>Masahiro Kondo</dc:creator>
                <dc:creator>Junichi Kitagawa</dc:creator>
                <dc:creator>Shigeji Matsumoto</dc:creator>
                <dc:creator>Azusa Kobayashi</dc:creator>
                <dc:creator>Barry Sessle</dc:creator>
                <dc:creator>Masamichi Shinoda</dc:creator>
                <dc:creator>Koichi Iwata</dc:creator>
                <dc:source>Molecular Pain 2010, 6:9</dc:source>
        <dc:date>2010-02-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-8069-6-9</dc:identifier>
        <prism:publicationName>Molecular Pain</prism:publicationName>
        <prism:issn>1744-8069</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2010-02-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularpain.com/content/6/1/8">
        <title>Trigeminal injury causes kappa opioid-dependent allodynic, glial and immune cell responses in mice  </title>
        <description>Background:
The dynorphin-kappa opioid receptor (KOR) system regulates glial proliferation after sciatic nerve injury. Here, we investigated its role in cell proliferation following partial ligation of infraorbital nerve (pIONL), a model for trigeminal neuropathic pain. Mechanical allodynia was enhanced in KOR gene deleted mice (KOR-/-) compared to wild type mice. Using bromodeoxyuridine (BrdU) as a mitotic marker, we assessed cell proliferation in three different areas of the trigeminal afferent pathway: trigeminal nucleus principalis (Vp), trigeminal root entry zone (TREZ), and trigeminal ganglion (TG).
Results:
In KOR-/- mice or norBNI-treated mice, the number of proliferating cells in the Vp was significantly less than in WT mice, whereas cell proliferation was enhanced in TREZ and TG. The majority of the proliferating cells were nestin positive stem cells or CD11b positive microglia in the Vp and macrophages in the TG. GFAP-positive astrocytes made a clear borderline between the CNS and the PNS in TREZ, and phosphorylated KOR staining (KOR-p) was detectable only in the astrocytes in CNS in WT mice but not in KOR-/- or norBNI-treated mice.
Conclusions:
These results show that kappa opioid receptor system has different effects after pIONL in CNS and PNS: KOR activation promotes CNS astrocytosis and microglial or stem cell proliferation but inhibits macrophage proliferation in PNS. The trigeminal central root has a key role in the etiology and treatment of trigeminal neuralgia, and these newly identified responses may provide new targets for developing pain therapies.</description>
        <link>http://www.molecularpain.com/content/6/1/8</link>
                <dc:creator>Aita Megumi</dc:creator>
                <dc:creator>Margaret Byers</dc:creator>
                <dc:creator>Charlse Chavkin</dc:creator>
                <dc:creator>Mei Xu</dc:creator>
                <dc:source>Molecular Pain 2010, 6:8</dc:source>
        <dc:date>2010-01-29T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-8069-6-8</dc:identifier>
        <prism:publicationName>Molecular Pain</prism:publicationName>
        <prism:issn>1744-8069</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>8</prism:startingPage>
        <prism:publicationDate>2010-01-29T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularpain.com/content/6/1/7">
        <title>Behavioral and anatomical characterization of the bilateral sciatic nerve chronic constriction (bCCI) injury: correlation of anatomic changes and responses to cold stimuli</title>
        <description>Background:
Unilateral constrictive sciatic nerve injury (uCCI) is a common neuropathic pain model. However, the bilateral constrictive injury (bCCI) model is less well studied, and shows unique characteristics. In the present study, we sought to correlate effects of bCCI on nocifensive responses to cold and mechanical stimuli with selected dorsal horn anatomic markers. bCCI or sham ligation of both rat sciatic nerves were followed up to 90 days of behavioural testing. Additional rats sacrificed at 15, 30 and 90 days were used for anatomic analyses. Behavioural tests included hindpaw withdrawal responses to topical acetone, cold plate testing, an operant thermal preference task and hindpaw withdrawal thresholds to mechanical probing.
Results:
All nocifensive responses to cold increased and remained enhanced for &gt;45 days. Mechanical withdrawal thresholds decreased for 25 days only. Densitometric analyses of immunoperoxidase staining in the superficial dorsal horn at L4-5 revealed decreased cholecystokinin (CCK) staining at all times after bCCI, decreased mu opiate receptor (MOR) staining, maximal at 15 days, increased neuropeptide Y (NPY) staining only at days 15 and 30, and increased neurokinin-1 receptor (NK-1R) staining at all time points, maximal at 15 days. Correlation analyses at 45 days post-bCCI, were significant for individual rat nocifensive responses in each cold test and CCK and NK-1R, but not for MOR or NPY.
Conclusions:
These results confirm the usefulness of cold testing in bCCI rats, a new approach using CCI to model neuropathic pain, and suggest a potential value of studying the roles of dorsal horn CCK and substance P in chronic neuropathic pain. Compared to human subjects with neuropathic pain, responses to cold stimuli in rats with bCCI may be a useful model of neuropathic pain.</description>
        <link>http://www.molecularpain.com/content/6/1/7</link>
                <dc:creator>Sukdeb Datta</dc:creator>
                <dc:creator>Koel Chatterjee</dc:creator>
                <dc:creator>Robert Kline</dc:creator>
                <dc:creator>Ronald Wiley</dc:creator>
                <dc:source>Molecular Pain 2010, 6:7</dc:source>
        <dc:date>2010-01-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-8069-6-7</dc:identifier>
        <prism:publicationName>Molecular Pain</prism:publicationName>
        <prism:issn>1744-8069</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2010-01-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularpain.com/content/6/1/6">
        <title>KATP channel subunits in rat dorsal root ganglia: 
alterations by painful axotomy
</title>
        <description>Background:
ATP-sensitive potassium (KATP) channels in neurons mediate neuroprotection, they regulate membrane excitability, and they control neurotransmitter release. Because loss of DRG neuronal KATP currents is involved in the pathophysiology of pain after peripheral nerve injury, we characterized the distribution of the KATP channel subunits in rat DRG, and determined their alterations by painful axotomy using RT-PCR, immunohistochemistry and electron microscopy.
Results:
PCR demonstrated Kir6.1, Kir6.2, SUR1 and SUR2 transcripts in control DRG neurons. Protein expression for all but Kir6.1 was confirmed by Western blots and immunohistochemistry. Immunostaining of these subunits was identified by fluorescent and confocal microscopy in plasmalemmal and nuclear membranes, in the cytosol, along the peripheral fibers, and in satellite glial cells. Kir6.2 co-localized with SUR1 subunits. Kir6.2, SUR1, and SUR2 subunits were identified in neuronal subpopulations, categorized by positive or negative NF200 or CGRP staining. KATP current recorded in excised patches was blocked by glybenclamide, but preincubation with antibody against SUR1 abolished this blocking effect of glybenclamide, confirming that the antibody targets the SUR1 protein in the neuronal plasmalemmal membrane.In the myelinated nerve fibers we observed anti-SUR1 immunostaining in regularly spaced funneled-shaped structures. These structures were identified by electron microscopy as Schmidt-Lanterman incisures (SLI) formed by the Schwann cells. Immunostaining against SUR1 and Kir6.2 colocalized with anti-Caspr at paranodal sites.DRG excised from rats made hyperalgesic by spinal nerve ligation exhibited similar staining against Kir6.2, SUR1 or SUR2 as DRG from controls, but showed decreased prevalence of SUR1 immunofluorescent NF200 positive neurons. In DRG and dorsal roots proximal to axotomy SLI were smaller and showed decreased SUR1 immunofluorescence.
Conclusions:
We identified Kir6.2/SUR1 and Kir6.2/SUR2 KATP channels in rat DRG neuronal somata, peripheral nerve fibers, and glial satellite and Schwann cells, in both normal state and after painful nerve injury. This is the first report of KATP channels in paranodal sites adjacent to nodes of Ranvier and in the SLI of the Schwann cells. After painful axotomy KATP channels are downregulated in large, myelinated somata and also in SLI, which are also of smaller size compared to controls.Because KATP channels may have diverse functional roles in neurons and glia, further studies are needed to explore the potential of KATP channels as targets of therapies against neuropathic pain and neurodegeneration.</description>
        <link>http://www.molecularpain.com/content/6/1/6</link>
                <dc:creator>Vasiliki Zoga</dc:creator>
                <dc:creator>Takashi Kawano</dc:creator>
                <dc:creator>Mei-Ying Liang</dc:creator>
                <dc:creator>Martin Bienengraeber</dc:creator>
                <dc:creator>Dorothee Weihrauch</dc:creator>
                <dc:creator>Bruce McCallum</dc:creator>
                <dc:creator>Geza Gemes</dc:creator>
                <dc:creator>Quinn Hogan</dc:creator>
                <dc:creator>Constantine Sarantopoulos</dc:creator>
                <dc:source>Molecular Pain 2010, 6:6</dc:source>
        <dc:date>2010-01-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-8069-6-6</dc:identifier>
        <prism:publicationName>Molecular Pain</prism:publicationName>
        <prism:issn>1744-8069</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2010-01-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
